Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

75.79 +2.72 (+3.72%)

Streaming Delayed Price Updated: 2:00 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

PTC Therapeutics (PTCT) Q1 2025 Earnings Call ↗

May 06, 2025

Via The Motley Fool

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? ↗

May 05, 2025

PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

May 05, 2025

Via Benzinga

Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗

May 05, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Earnings Preview For PTC Therapeutics ↗

November 06, 2024

Via Benzinga

These stocks are gapping in today's session ↗

May 05, 2025

The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

These stocks that are showing activity before the opening bell on Monday. ↗

May 05, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

9 Health Care Stocks With Whale Alerts In Today's Session ↗

April 22, 2025

Via Benzinga

European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder ↗

March 28, 2025

PTC Therapeutics' Translarna loses EU conditional approval, but countries may allow continued use. PTC submitted four FDA applications, all under review.

Via Benzinga

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July ↗

March 20, 2025

PTC Therapeutics presented new Phase 3 data on sepiapterin, showing potential benefits for PKU patients ahead of key regulatory decisions in 2025.

Via Benzinga

This GE HealthCare Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

March 11, 2025

Via Benzinga

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗

December 10, 2024

The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval.

Via Investor's Business Daily

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗

December 06, 2024

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

Via Benzinga

Bank of America To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

December 03, 2024

Via Benzinga

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program ↗

December 02, 2024

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including milestones and royalties.

Via Benzinga

XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗

December 02, 2024

Via Benzinga

PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone ↗

December 02, 2024

The deal focuses on the company's treatment for Huntington's disease.

Via Investor's Business Daily

PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs ↗

November 27, 2024

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.

Via Benzinga

FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain ↗

November 14, 2024

PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.

Via Benzinga

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗

August 19, 2024

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 10, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 03, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again ↗

June 28, 2024

The company plans to ask for another re-examination for its drug in Europe.

Via Investor's Business Daily

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday ↗

June 21, 2024

Via Benzinga

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder ↗

June 20, 2024

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.